{"entity":{"id":"nct06568692","kind":"trial","name":"A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer","aka":[],"tldr":"A phase 2 trial of Capecitabine in triple-negative breast cancer, run by Processa Pharmaceuticals, now recruiting.","summary":"A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT06568692 by Processa Pharmaceuticals, with 90 participants planned, started 2024-10-02 and due to reach its primary completion in 2026-09. Interventions recorded: PCS6422 and capecitabine and Capecitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06568692","url":"https://clinicaltrials.gov/study/NCT06568692"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06568692","phase":"2","setting":"A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer","sponsor":"Processa Pharmaceuticals","started":"2024-10-02","startedType":"actual","enrolled":90,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06568692/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"}]}}